Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — AES Investor Breakfast 2022

35 slides from Marinus Pharmaceuticals's conference presentation, Dec 5, 2022

  1. Slide 1: AES Investor Breakfast

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder AES Investor Breakfast December 5, 2022

  2. Slide 2: Forward-looking statements

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe

  3. Slide 3: Agenda

    Agenda Welcome & Introduction Sasha Damouni Ellis, VP, Corporate Affairs & Investor Relations CDKL5 Deficiency Disorder: Phase 3 Open - Label Extension Alex Aimetti, Ph.D. VP, Scientific Affairs Tuberous Sclerosis Complex: DDI Study Results Ian Miller, M.D., VP, Clinical Development Second Generatio

  4. Slide 4: CDKL5 Deficiency Disorder: Phase 3 Open-Label Extension

    CDKL5 Deficiency Disorder: Phase 3 Open - Label Extension Alex Aimetti, Ph.D. VP, Scientific Affairs

  5. Slide 5: AES 2022 Marinus Abstract Highlights

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I AES 2022 Marinus Abstract Highlights 5 • Dose - dependent pharmacokinetic and pharmacodynamic response following administration of IV ganaxolone in healthy volunteers • More pronounced BIS/ qEEG changes observed following IV bolus suggesting

  6. Slide 6: Emerging Data from Marigold OLE: 2 Year Minimum Follow-up

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Updated analysis (data cut June 2022) provides a 2 - year analysis of safety and effectiveness of ganaxolone in patients with CDD Emerging Data from Marigold OLE*: 2 Year Minimum Follow - up 6 DEMOGRAPHIC & BASELINE CHARACTERISTICS OPEN - LAB

  7. Slide 7: Ganaxolone Showed Sustained Reductions in CDD-associated Seizure Frequency at 2 Years

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Ganaxolone Showed Sustained Reductions in CDD - associated Seizure Frequency at 2 Years 7 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 0 10 20 30 40 50 60 70 80 90 100 Time Interval in the Open-Label Extension (months) Percent reduction in major

  8. Slide 8: Ganaxolone Showed Sustained Reductions in CDD-associated Seizure Frequency at 2 Years

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 0 10 20 30 40 50 60 70 80 90 100 Time Interval in the Open-Label Extension (months) Percent reduction in major motor seizure frequency All Available Data LOCF n=87 All Available Data n=79 n=73 n=67 LO

  9. Slide 9: Response Rates Suggest Robust Reductions in CDD-associated Seizure Frequency

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Response Rates Suggest Robust Reductions in CDD - associated Seizure Frequency 9 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 0 10 20 30 40 50 60 70 80 90 100 Time Interval in the Open-Label Extension (months) Proportion of Patients Achieving x%

  10. Slide 10: Open-Label Extension Safety Summary

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Open - Label Extension Safety Summary 10 T REATMENT - EMERGENT A DVERSE E VENTS N (%) Vomiting 20 (22.7) Somnolence 19 (21.6) Pyrexia 15 (17.0) Decreased appetite 9 (10.2) Covid - 19 14 (15.9) Upper Respiratory Tract Infection 14 (15.9) Nasop

  11. Slide 11: Marigold 2-Year Open-Label Extension Takeaways

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I ► Ganaxolone was generally well - tolerated in the OLE with safety findings consistent with those observed in the double - blind phase and the known safety profile of ganaxolone ► Patients on ganaxolone at 2 years in the OLE (n=50) showed a m

  12. Slide 12: Tuberous Sclerosis Complex DDI Study & Phase 3 TrustTSC Trial

    Tuberous Sclerosis Complex DDI Study & Phase 3 TrustTSC Trial Ian Miller, M.D., VP, Clinical Development 12

  13. Slide 13: TSC Phase 2 Trial Results

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 13 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC - associated

  14. Slide 14: Phase 1 DDI Results: No Clinically Meaningful GNX-CBD Interaction Observed

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Cannabidiol PK Ganaxolone PK ► Plasma levels of ganaxolone were slightly lower when co - administered with cannabidiol • Ganaxolone C max was 10% lower when co - administered cannabidiol • Ganaxolone AUC 0 - t was 19% lower when co - administ

  15. Slide 15: Phase 3 Protocol Refinements Informed by Phase 2

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 15 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy 0 7 14 21 28 35 0 20 40 60 80 100 Time (days) Approx. % Max GNX Dose TSC Ph2 Titration TSC Ph3 Titration

  16. Slide 16: Second Generation Product Development

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Second Generation Product Development Joseph Hulihan, M.D., Chief Medical Officer

  17. Slide 17: Approaches to Second Generation Ganaxolone Development

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I ► Reformulation • Goals – Consistent dose - exposure relationship – Ability to individualize dosing – Dose once - or twice - daily – Reduce peak/trough variability • Two candidates selected for clinical assessment ► Prodrug • Goal is to devel

  18. Slide 18: Reformulation Candidate 1: Phase 1 Data (Cohorts 1 and 2)

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Pharmacokinetic objectives ► Evaluate single - dose PK and compare to the current oral suspension (reference formulation) • Doses of 100 to 900mg • With or without food (high - fat meal) ► Parameters evaluated • Cmax • Tmax • AUC Reformulatio

  19. Slide 19: Reformulation Candidate 1: Phase 1 Data (Cohorts 1 and 2)

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Reformulation Candidate 1: Phase 1 Data (Cohorts 1 and 2) 19 0 2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0 2 0 0 0 1 2 2 4 3 6 4 8 P l a s m a g a n a x o l o n e c o n c e n t r a t i o n ( n g / m L ) H o u r s R e f o r m u l a t i o n 1

  20. Slide 20: Ganaxolone Second Generation Formulation

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Second Generation Formulation 20 However, increases in Cmax get progressively smaller as the dose increases AUC increases linearly throughout the range of doses administered These Phase 1 results support testing PK at higher doses, whic

  21. Slide 21: Reformulation Candidate 1: Phase 1 Study (Cohort 3)

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Pharmacokinetic objectives ► Evaluate single - dose PK of reformulation 1 and oral suspension in fed state (high - fat meal) at higher doses of 900 and 1200 mg ► Dosage forms tested (all in fed state) • Oral suspension • Sprinkle in water or with

  22. Slide 22: Approach to Prodrug Development

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Two prodrug candidates identified: ► Compound 1 • Slow conversion • > 24 - hour exposure • Converted by human and dog microsomes (human 3x faster than dog) ► Compound 2 • Rapid conversion • Converted by human and dog microsomes • In vivo animal st

  23. Slide 23: ZTALMY Launch Update

    Not for promotional use ZTALMY ® (ganaxolone) oral suspension CV Launch Update Christy Shafer, Chief Commercial Officer

  24. Slide 24: Progress Indicators Following July Commercial Launch

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Progress Indicators Following July 28 Commercial Launch 24 More than 50 prescription enrollment forms received for patients with CDD Over 30 new commercial patient enrollments Demand coming from over 40 unique accounts Positive coverage crite

  25. Slide 25: ZTALMY Early Success Metrics & Key Field Insights

    Not for promotional use ZTALMY Early Success Metrics & Key Field Insights Lisa Lejuwaan, VP, Sales

  26. Slide 26: ZTALMY Early Success Metrics & Key Field Insights

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I ZTALMY Early Success Metrics & Key Field Insights 26 1 Symonds JD 2019 Brain *Estimated based on Symonds JD 2019 Brain CDD ‘A’ Accounts (40) • National Association of Epilepsy Centers • Largest # of patient claims • Early adopters • High infl

  27. Slide 27: ZTALMY Market Access & Patient Services Update

    Not for promotional use ZTALMY Market Access Patient Services Update Paul Voss, VP, Access & Policy

  28. Slide 28: ZTALMY Market Access & Patient Services Update

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I ZTALMY Market Access & Patient Services Update As of December 1, 2022 (since July 28 launch) Commercial + PBM Government – Medicaid (FFS & Managed) 57% of commercial lives with confirmed coverage 20 plans = ~73M Lives Very Limited Access 7.4M

  29. Slide 29: ZTALMY Customer Engagement, Digital & AES Footprint

    Not for promotional use ZTALMY Customer Engagement, Digital & AES Footprint Catherine Galica, Sr. Director, Marketing Genetic Epilepsy

  30. Slide 30: ZTALMY Live Engagements

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Exhibitor Booth Product Theater Key Opinion Leader Engagement Peer to Peer Programs Q4 2022 ZTALMY Live Engagements 30 Presenter: Steven Wol f, MD Director of Ped. Epilepsy at Boston Children’s Health Physicians of NY & CT 20+ KOL engagements

  31. Slide 31: ZTALMY Website Performance Summary

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I ZTALMY Website Performance Summary 31 *Known staging traffic and actions excluded. Numbers may look different from GA4 reporting. GA4 Engaged Sessions = number of sessions that last at least 10 seconds, or have 1 or more conversion events, or

  32. Slide 32: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches Kristin Rudisill, VP, Acute Care

  33. Slide 33: Preparing for Commercial Readiness: Refractory Status Epilepticus (RSE)

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Preparing for Co mmercial Readiness: Refractory Status Epilepticus (RSE) 33 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol .. 1995; 12: 316 - 325 2. Kapur et al. Randomized Trial of Three

  34. Slide 34: Key Considerations to Support Commercial Readiness for IV Franchise

    ©2022 Marinus Pharmaceuticals, Inc. All Rights Reserved I Key Considerations to Support Commercial Readiness for IV Franchise 34 Defining the Value Proposition Clinical Differentiation Economic Benefits Total Value Proposition Pricing Considerations ► Conducting ongoing pricing research to support o

  35. Slide 35: Q&A

    Q&A (© MARINUS

Marinus Pharmaceuticals — AES Investor Breakfast 2022 on 6ix